# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Review Proposal Project

NICE Technology Appraisal TA433; Apremilast for treating active psoriatic arthritis), TA445; Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying anti-rheumatic drugs

## Stakeholder list

#### **Consultees**

## Company/sponsor

- Celgene (Apremilast)
- Novartis (Certolizumab pegol
- UCB Pharma (Secukinumab)

# Patient/carer groups

- Muslim Council of Britain
- Psoriasis Association
- Psoriasis and Psoriatic Arthritis Alliance
- South Asian Health Foundation
- Specialised Healthcare Alliance

## **Professional groups**

- British Association of Dermatologists
- British Geriatrics Society
- British Society for Rheumatology
- Primary Care Rheumatology Society
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine

UK Clinical Pharmacy Association

#### **Others**

## **Department of Health and Social Care**

- Department of Health and Social Care
- NHS Birmingham CrossCity CCG
- NHS England
- NHS Shropshire CCG
- Welsh Government

#### **Commentators**

#### **General commentators**

- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare Products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Alliance
- NHS Confederation
- Scottish Medicines Consortium
- Welsh Health Specialised Services Committee

## **Comparators**

- Abbvie (adalimumab)
- Celgene (apremilast)
- Janssen (ustekinumab)
- Merck Sharp & Dohme (golimumab, infliximab)
- Napp Pharmaceuticals (infliximab)

# Relevant research groups

- Genomics England
- MRC Clinical Trials Unit
- National Institute for Health Research

# **Associated Public Health groups**

- Public Health England
- Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.